Effect of telmisartan on patients with renal dysfunctio
Not Applicable
- Conditions
- Chronic Kidney Disease
- Registration Number
- JPRN-UMIN000040875
- Lead Sponsor
- agasaki University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 73
Inclusion Criteria
Not provided
Exclusion Criteria
heavy liver dysfunction and/or poor bile secretion, possibility of pregnancy or lactation, past history of hypersensitivity for telmisartan or its analogous drugs, nephrotic proteinuria, corticosteroids or immunosuppressant agents within the past 6 months, acute myocardial infarction within 6 months, congestive heart failure, cerebral infarction, transient ischemic attack, and renal artery stenosis
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method A composite of doubling serum creatinine, transition to chronic kidney disease stage 5, the onset of end-stage renal disease, or death from any causes within 104 weeks.
- Secondary Outcome Measures
Name Time Method Amount of urinary protein, and decreased eGFR during the 104 weeks.